We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 1,080

IP in depth: patentable biotechnology a comparative analysis of key markets

  • Fisher Adams Kelly
  • -
  • Australia, European Union, New Zealand, USA
  • -
  • March 31 2015

There is extraordinary complexity and optimization underlying even comparatively 'simple' organisms. These powerful biological products and processes

Patent and pharma update March 2015

  • Herbert Smith Freehills LLP
  • -
  • European Union, United Kingdom
  • -
  • March 27 2015

The ongoing dispute between Warner-Lambert and Actavis concerns developing law on how patents covering the second medical use of a

EPO Enlarged Board affirms patentability of plant claims

  • FRKelly
  • -
  • European Union
  • -
  • March 27 2015

The Enlarged Board has issued decisions on 25 March 2015 on: G 212 (Tomatoes II) and G 213 (Broccoli II) and, in so doing, has brought welcome

Tomatoes II (G 000212) and Broccoli II (G 000213): European Patent Office’s decisions

  • Stibbe
  • -
  • European Union
  • -
  • March 27 2015

The Enlarged Board of Appeal of the European Patent Office has taken two decisions this Wednesday (25 March 2015) highly anticipated by the

SPCs to combinations of active ingredients available only if the combination constitutes the “subject matter of the invention” in the patent

  • Potter Clarkson LLP
  • -
  • European Union
  • -
  • March 27 2015

On 12 March 2015, the Court of Justice of the European Union (CJEU) handed down its judgment in Actavis v Boehringer (C-57713). The Court has

EPO resolves split regarding clarity

  • Fish & Richardson PC
  • -
  • European Union
  • -
  • March 26 2015

The European Patent Office (EPO) has resolved an internal split of opinions regarding when issues of lack of clarity can be raised in opposition

G 314: clarity from the Enlarged Board

  • FRKelly
  • -
  • European Union
  • -
  • March 26 2015

About 70 of EPO oppositions involve the claims being amended. An opponent or an opposition division may wish to object that the claims are unclear

Revisiting toxic divisionals

  • Marks & Clerk
  • -
  • European Union
  • -
  • March 25 2015

The subject of toxic (or "poisonous") divisional applications was a popular topic of discussion in the IP world at the end of 2013. Since then, it

Unitary patent: on course for 2016

  • Marks & Clerk
  • -
  • European Union, Luxembourg
  • -
  • March 24 2015

On 18 March 2015 Luxembourg became the seventh country to ratify the Unified Patent Court Agreement. With this, the Unitary Patent has come one step

The ECJ in Actavis v. Boehringer on supplementary protection certificates

  • Martini Manna Avvocati
  • -
  • European Union
  • -
  • March 17 2015

On 12 March, the Court of Justice of the European Union ("ECJ") ruled on the possibility of issuing a valid supplementary protection certificate